Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

Fine-Tuning Liver Glucose Metabolism

By Biotechdaily staff writers
Posted on 30 Jun 2006
Researchers have traced the biochemical mechanism responsible for modulating the uptake, release, and synthesis of glucose by the liver.

Previous findings had shown that hormonal and nutrient regulation of glucose synthesis in the liver was controlled by modulation of the transcriptional coactivator protein PGC-1-alpha. In the current study, investigators at Johns Hopkins University (Baltimore, MD, USA) learned that PGC-1-alpha resides in a multi-protein complex containing the acetyltransferase GCN5. Fine-tuning of glucose metabolism depends on inactivation of PGC-1-alpha by this enzyme and its subsequent sequestering away from the genes it was normally meant to activate.

This mechanism was demonstrated experimentally by using an adenovirus vector to implant the gene for GCN5 into the livers of a group of starved mice. Normally such animals are actively releasing glucose into the blood, but results published in the June 2006 issue of Cell Metabolism showed that glucose release in these genetically engineered animals was significantly reduced.

"These results show that changing GCN5 is sufficient to control the sugar balance in mice,” explained senior author Dr. Pere Puigserver, assistant professor of cell biology at Johns Hopkins University. "Therefore, GCN5 has the potential to be a target for therapeutic drug design in the future. Understanding the ways that energy production and use are controlled is crucial to developing new drugs and therapies.”



Related Links:
Johns Hopkins University

Channels

Genomics/Proteomics

view channel
Image: Cancer cells, left, were pretreated with a drug that blocks the ERK signal, and right, without the pretreatment. Top cells are untreated, while the bottom ones are stimulated (Photo courtesy of the Weizmann Institute of Science).

Prevention of ERK Nuclear Translocation Blocks Cancer Proliferation in Animal Models

A team of cell biologists has shown that the cancer promoting effects of ERK dysregulation can be blocked by low molecular weight drugs that prevent translocation of this kinase from the cells' cytoplasm... Read more

Drug Discovery

view channel
Image: Star-like glial cells in red surround alpha-beta plaques in the cortex of a mouse with a model of Alzheimer\'s disease (Photo courtesy of Strittmatter laboratory/Yale University).

Experimental Cancer Drug Reverses Symptoms in Mouse Model of Alzheimer's Disease

An experimental, but clinically disappointing drug for treatment of cancer has been found to be extremely effective in reversing the symptoms of Alzheimer's disease (AD) in a mouse model.... Read more

Business

view channel

NanoString and MD Anderson Collaborate on Development of Novel Multi-Omic Expression Profiling Assays for Cancer

The University of Texas MD Anderson Cancer Center (Houston, TX, USA) and NanoString Technologies, Inc. (Seattle, WA, USA) will partner on development of a revolutionary new type of assay—simultaneously profiling gene and protein expression, initially aiming to discover and validate biomarker signatures for immuno-oncology... Read more
 

Events

21 Apr 2015 - 23 Apr 2015
21 Apr 2015 - 23 Apr 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.